An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Completed · Phase 3 · Has a placebo group

Conditions studied: Generalized Anxiety Disorder

In brief

The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.

Key facts

Study ID

NCT00734071

Run by

Takeda

People needed

304

Starts

2008-06-01

Expected to finish

2009-03-01

Last updated by the study team

2013-12-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has a primary diagnosis of Generalized Anxiety Disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR®) criteria.
• Has a Hamilton Anxiety Scale total score greater than or equal to 20 at Screening and Baseline.
• Has a Hamilton Anxiety Scale score greater than or equal to 2 on both Item 1 (anxious mood) and Item 2 (tension) at Screening and Baseline.
• Has a Montgomery-Åsberg Depression Rating Scale total score less than or equal to 16 at Screening and Baseline.

You may not qualify if…

• Has 1 or more of the following:
• Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the DSM-IV-TR (as assessed by the Mini International Neuropsychiatric Interview [MINI]).
• Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
• Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR® and subject must have a negative urine drug screen prior to Baseline.
• Presence or history of a clinically significant neurological disorder (including epilepsy).
• Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc.).
• Any Axis II disorder that might compromise the study.
• Is taking excluded medications.
• Has a significant risk of suicide according to the investigator's opinion or has a score greater than or equal to 5 on Item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
• Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
• Has received electroconvulsive therapy within 6 months prior to Screening.
• Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
• Has a clinically significant unstable illness.
• Has an alanine aminotransferase, aspartate aminotransferase, or total bilirubin level greater than 1.5 times the upper limit of normal.
• Has a serum creatinine of greater than 1.5 times the upper limit of normal.
• Has a previous history of cancer that had been in remission for less than 5 years.
• Has thyroid stimulating hormone value outside the normal range at Screening and is deemed clinically significant by the investigator.
• Has an abnormal electrocardiogram.

Where it is running

• Study site — Anaheim, California, United States
• Study site — Arcadia, California, United States
• Study site — Irvine, California, United States
• Study site — National City, California, United States
• Study site — Sherman Oaks, California, United States
• Study site — Upland, California, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Bradenton, Florida, United States
• Study site — Coral Gables, Florida, United States
• Study site — North Miami, Florida, United States
• Study site — St. Petersburg, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Oak Brook, Illinois, United States
• Study site — Park Ridge, Illinois, United States
• Study site — Lafayette, Indiana, United States
• Study site — Wichita, Kansas, United States
• Study site — Baltimore, Maryland, United States
• Study site — Fall River, Massachusetts, United States
• Study site — Worcester, Massachusetts, United States
• Study site — Flowood, Mississippi, United States
• Study site — Brooklyn, New York, United States
• Study site — New York, New York, United States
• Study site — The Bronx, New York, United States
• Study site — Morganton, North Carolina, United States
• Study site — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.